Xenter, a Draper, Utah TechMed company building a clinical AI platform paired with wireless medical devices, has closed a $58.25 million Series B, giving it the runway to launch its diagnostics business and start clinical testing of its dual-sensor guidewire in a red-hot cardiac-procedure market.
The Round
The financing closed on June 30 and was announced July 16. Backers, described only as existing shareholders, prominent family offices and healthcare investors, were not disclosed. Xenter also appointed Linda Vega to its board of directors alongside the close. Founded in 2020 by chief executive Richard J. Linder, the company has now stitched together enough capital to fund the commercial launch of its diagnostics unit and manufacturing expansion.
Inside The TechMed Platform
Xenter’s pitch is a scalable clinical intelligence layer that fuses medical devices, data infrastructure and clinical AI. Its platform ingests real-time high-fidelity procedural data from wireless sensors and connects that data across the continuum of care, so every case adds to a growing library of procedural, diagnostic and outcome information. The company positions the system as a way for providers and health systems to make faster, better-supported decisions inside cath labs and operating rooms.
Guru Guidewire Enters The Clinic
The most notable near-term milestone is the initiation of planned clinical testing of the Guru dual-sensor physiology guidewire in Transcatheter Aortic Valve Replacement (TAVR) procedures. TAVR volumes are surging as populations age, and structural-heart operators are hungry for better real-time hemodynamic data — exactly the niche Xenter is targeting, and a use case that pulls the company squarely into the accelerating physical-AI-in-medicine narrative.
Why It Matters
Clinical AI has attracted headline funding for imaging and administrative use cases, but hardware-plus-software players that sit inside the procedure remain rare. Xenter’s combination of a diagnostic sensor guidewire and a data platform gives it a foothold in one of the most valuable pieces of the interventional cardiology stack, at the same time device incumbents such as Medtronic are racing to bolt AI onto their own procedure kits.
Reporting based on coverage from FinSMEs, PR Newswire and Xenter.